메뉴 건너뛰기




Volumn 17, Issue 4, 2003, Pages 276-281

Simultaneous determination of leflunomide and its active metabolite, a77 1726, in human plasma by high-performance liquid chromatography

Author keywords

Isoxazol derivative; Metabolism; Pharmacokinetics; Rheumatoid arthritis

Indexed keywords

DISEASES; METABOLITES; PATIENT TREATMENT; PLASMA (HUMAN);

EID: 0038048455     PISSN: 02693879     EISSN: None     Source Type: Journal    
DOI: 10.1002/bmc.244     Document Type: Article
Times cited : (57)

References (16)
  • 3
    • 0029852104 scopus 로고    scopus 로고
    • Lefunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis
    • Bartlett RR, Brendel S, Zielinski T and Schorlemmer HU. Lefunomide, an immunorestoring drug for the therapy of autoimmune disorders, especially rheumatoid arthritis. Transplantation Proceedings 1996; 28: 3074-3078.
    • (1996) Transplantation Proceedings , vol.28 , pp. 3074-3078
    • Bartlett, R.R.1    Brendel, S.2    Zielinski, T.3    Schorlemmer, H.U.4
  • 5
    • 0033764113 scopus 로고    scopus 로고
    • Leflunomide: Mode of action in the treatment of rheumatoid arthritis
    • Breedveld FC and Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Annals of Rheumatic Disease 2000; 59: 841-849.
    • (2000) Annals of Rheumatic Disease , vol.59 , pp. 841-849
    • Breedveld, F.C.1    Dayer, J.M.2
  • 8
    • 0030032806 scopus 로고    scopus 로고
    • The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase
    • Davis JP, Cain GA, Pitts WJ, Magolda RL and Copeland RA. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase. Biochemistry 1996; 35: 1270-1273.
    • (1996) Biochemistry , vol.35 , pp. 1270-1273
    • Davis, J.P.1    Cain, G.A.2    Pitts, W.J.3    Magolda, R.L.4    Copeland, R.A.5
  • 9
    • 0028853980 scopus 로고
    • Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography
    • Dias VC, Lucien J, LeGatt DF and Yatscoff RW. Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 1995; 17: 84-88.
    • (1995) Therapeutic Drug Monitoring , vol.17 , pp. 84-88
    • Dias, V.C.1    Lucien, J.2    LeGatt, D.F.3    Yatscoff, R.W.4
  • 10
    • 85161747740 scopus 로고    scopus 로고
    • Clinical pharmacology/biopharmaceutics review. Arava® Leflunomide tablets; summary basis of approval equivalent
    • FDA. Study YU#204. FDA Summary Basis of Approval. NDA: 20-905
    • FDA. Study YU#204. Clinical pharmacology/biopharmaceutics review. Arava® Leflunomide tablets; summary basis of approval equivalent. FDA Summary Basis of Approval. NDA: 20-905, 1998.
    • (1998)
  • 11
    • 0029050136 scopus 로고
    • Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide
    • Green S, Watanabe K, Braatz-Trulson J and Lou L. Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide. Biochemical Pharmacology 1995; 50: 861-967.
    • (1995) Biochemical Pharmacology , vol.50 , pp. 861-967
    • Green, S.1    Watanabe, K.2    Braatz-Trulson, J.3    Lou, L.4
  • 13
    • 0027501428 scopus 로고
    • Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide
    • Mattar T, Kochhar K, Bartlett RR, Bremer EG and Finnegan A. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Letters 1993; 334: 161-164.
    • (1993) FEBS Letters , vol.334 , pp. 161-164
    • Mattar, T.1    Kochhar, K.2    Bartlett, R.R.3    Bremer, E.G.4    Finnegan, A.5
  • 15
    • 12644249109 scopus 로고    scopus 로고
    • In vitro and in vivo effects of leflunomide, brequinar and cyclosporine on pyrimidine biosynthesis
    • Silva HT Jr, Cao W, Shorthouse RA, Loffler M and Morris RE. In vitro and in vivo effects of leflunomide, brequinar and cyclosporine on pyrimidine biosynthesis. Transplantation Proceedings 1997; 29: 1292-1293.
    • (1997) Transplantation Proceedings , vol.29 , pp. 1292-1293
    • Silva H.T., Jr.1    Cao, W.2    Shorthouse, R.A.3    Loffler, M.4    Morris, R.E.5
  • 16
    • 0031180972 scopus 로고    scopus 로고
    • In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in Mrl/MpJ-Ipr/lpr mice
    • Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW and Chong AS. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in Mrl/MpJ-Ipr/lpr mice. Journal of Immunology 1997; 159: 167-174.
    • (1997) Journal of Immunology , vol.159 , pp. 167-174
    • Xu, X.1    Blinder, L.2    Shen, J.3    Gong, H.4    Finnegan, A.5    Williams, J.W.6    Chong, A.S.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.